Table 1 Baseline characteristics of study participants
From: The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD
Total (N = 489) | |
|---|---|
Age, years | 67.3 ± 11.6 |
Male | 309 (63.2) |
Ethnicity, white | 391 (81.0) |
Smoking status | |
Current smoker | 287 (58.7) |
Ex-smoker | 173 (35.4) |
Never smoker | 29 (5.9) |
Asthma | 119 (24.4) |
Cardiac comorbidities* | 182 (37.3) |
Lung function | |
Post-bronchodilator FVC, L | 2.8 ± 1.1 |
Post-bronchodilator FVC, %predicted | 77.6 ± 23.1 |
Post-bronchodilator FEV1, L | 1.5 ± 0.8 |
Post-bronchodilator FEV1, %predicted | 53.7 ± 23.8 |
Post-bronchodilator FEV1/FVC | 45.2 ± 24.8 |
IgG subclass deficiency | |
IgG1 deficiency | 9 (1.8) |
IgG2 deficiency | 59 (12.1) |
IgG3 deficiency | 21 (4.3) |
IgG4 deficiency | 55 (11.3) |
1-year mortality | 101 (20.7) |